Gudiwada Mohan Chandra Vinay Bharadwaj, Gaddam Vinuthna, Rahman Maheen, Jasti Jaswanth R, Bhalodia Paritaben, Jitta Sahas Reddy
Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, USA.
Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, USA.
Cureus. 2023 May 17;15(5):e39150. doi: 10.7759/cureus.39150. eCollection 2023 May.
Current literature suggests an increased incidence of rhabdomyolysis in patients with chronic liver disease (CLD) compared to the general population. We present a case of a 60-year-old female with a history of non-alcoholic fatty liver disease and cirrhosis who developed rhabdomyolysis and acute kidney injury after starting high-intensity atorvastatin therapy. This case highlights the potential risks associated with high-intensity statin therapy in patients with CLD, particularly those with advanced liver dysfunction, emphasizing the need for cautious prescribing and thorough risk-benefit assessment in this vulnerable patient population.
当前文献表明,与普通人群相比,慢性肝病(CLD)患者横纹肌溶解症的发病率有所增加。我们报告一例60岁女性病例,该患者有非酒精性脂肪性肝病和肝硬化病史,在开始高强度阿托伐他汀治疗后发生横纹肌溶解症和急性肾损伤。该病例突出了CLD患者,尤其是那些有晚期肝功能障碍的患者,接受高强度他汀类药物治疗所带来的潜在风险,强调了在这一脆弱患者群体中谨慎开药和全面进行风险效益评估的必要性。